19F Thoracic Radiotherapy for Lung Cancer
The goal of this study is to determine the feasibility and efficiency of incorporating 19F MR functional lung imaging into the routine assessment of lung cancer patients prior to thoracic radiotherapy.
Checked against the public recordLast updated Jul 16, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- Hal C Charles
- Interventions being studied
- Drug: Perfluorinated Gas/Oxygen Mixture
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subject has histologic or cytologic confirmation of lung cancer (NSCLC or Small cell) and has been recommended thoracic radiotherapy as part of standard of care management. * Ability to undergo MR imaging, tolerate breath hold procedures and follow direction during the imaging process * Karnofsky performance status ≥60, with expected survival of ≥6 months * At least 18 years of age * Patient is not pregnant * Patient can be reliably reached for post-MRI follow up AE check. * Patient able to sign a study specific informed consent form. Exclusion Criteria: * Any condition including, metallic implants or cardiac pacemakers that makes the candidate ineligible for MR imaging. (MRI research screening form will be completed prior to each MRI scan). * Malignant pleural effusion or pericardial effusion
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Duke University Medical Center - Cancer CenterDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 16, 2019. Always confirm current availability with the study team.